Surgical site infections (SSIs) are among the most common and costly complications following elective procedures—leading to prolonged hospital stays, repeat surgeries, and delayed recovery. But a new solution may be changing that narrative for good.

In a recent Phase 3 clinical trial, a product called D-PLEX₁₀₀—a novel, drug-eluting surgical barrier developed by PolyPid—demonstrated a 58% reduction in postoperative infections among patients undergoing large abdominal surgeries.

The study, known as SHIELD II, involved 1,800 patients across multiple hospitals and showed that D-PLEX₁₀₀ dramatically reduced deep and superficial infections in the 30-day post-op period. With this result, PolyPid plans to submit the product for FDA approval in early 2026.

💡 What Is D-PLEX₁₀₀ and How Does It Work?

D-PLEX₁₀₀ is an antibiotic-eluting film applied directly to the surgical site before closure. It slowly releases doxycycline over a 30-day period, delivering localized, high-concentration protection without relying on systemic antibiotics.

Its key advantages:

• ✅ Sustained-release: Maintains protective levels of antibiotics exactly where needed
• ✅ Localized action: Reduces systemic side effects and antibiotic resistance risks
• ✅ No change to surgical workflow: Easily applied by surgeons within minutes

🌟 Why This Matters for Elective Surgery Patients

Patients undergoing elective surgeries—especially abdominal, orthopedic, or plastic procedures—often face infection risks despite pre-op antibiotics. D-PLEX₁₀₀ offers a major leap in post-op safety, with benefits including:

• ✅ Faster recovery
• ✅ Fewer complications or readmissions
• ✅ Shorter hospital stays
• ✅ Greater peace of mind during elective procedures

This technology could soon become a new standard of care in clean-contaminated surgeries, where infections are frequent and costly.

🔍 What’s Next?

PolyPid’s submission for regulatory approval is expected in early 2026, with experts predicting wide adoption in both public and private surgical centers. As infection prevention becomes more precise, patients can expect safer outcomes and more predictable healing—especially important for international patients seeking elective surgery abroad.

💬 FlytoDoc Insight

At FlytoDoc, we continuously monitor surgical innovations that improve safety, comfort, and long-term results. We believe technologies like D-PLEX₁₀₀ will play a key role in reducing risks and ensuring high standards of care across our partner hospitals worldwide.

🔗 Explore Safe & Modern Surgery Options with FlytoDoc

Source:
PolyPid Official website